Baxter International (BAX) : The total money flow in Baxter International (BAX) was negative ($21.23 million), which signals selling by the traders on Thursdays session. They trimmed their holdings by selling the stock on downticks to the tune of $33.89 million. In comparison, the inflow of money into the stock on upticks was $12.66 million. The uptick to downtick ratio was 0.37. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $21.97 million. The value of transactions on uptick was $0.64 million. The negative money flow of ($21.33 million) confirms the selling in Baxter International (BAX) on strength. The uptick to downtick ratio of block trades was 0.03. Baxter International (BAX) gained $0.13 at $46.12, a gain of 0.28% over the previous days close. However, the stock registered 1.47% in the week.
Baxter International (BAX) : 6 investment research analysts covering Baxter International (BAX) have an average price target of $48.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $60 and the lowest target is $46 for the short term. Analysts expect the variance to be within $5.49 of the average price. The stock has recorded a 20-day Moving Average of 3.27% and the 50-Day Moving Average is 3.95%.
Baxter International (NYSE:BAX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $45.92 and $45.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $46.36. The buying momentum continued till the end and the stock did not give up its gains. It closed at $46.12, notching a gain of 0.28% for the day. The total traded volume was 2,485,362 . The stock had closed at $45.99 on the previous day.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.